alexa Abstract | A Retrospective Analysis of the Incidence of Clostridium Difficile Associated Diarrhea with Meropenem and Piperacillin-tazobactam

International Journal of Collaborative Research on Internal Medicine & Public Health
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Abstract

Introduction: Meropenem and piperacillin-tazobactam have similar indications, spectrum of antimicrobial actions, and cost. When selecting between two antibiotics with similar efficacy, one may want the antibiotic with the least harm, such as C. difficile associated diarrhea (CDAD).

Aim & Objectives: This study tested the hypothesis that patients on piperacillintazobactam had a lower incidence of CDAD than patients on meropenem.

Methods: A retrospective analysis was performed that included patients who received meropenem or piperacillin-tazobactam during their admissions to Ridge Meadows Hospital, Canada from September 2007 to August 2009. This study had a subgroup analysis on patients with risk factors of developing CDAD: male, over 65 years old, staying longer than 28 days in healthcare settings, receiving concurrent risk factor medications, not on Saccharomyces boulardii in the previous two months, and not on oral metronidazole, intravenous metronidazole, or oral vancomycin in the previous two months.

Results: There were 168 patients in the meropenem group and 122 patients in the piperacillin-tazobactam group. No significant difference was found between meropenem and piperacillin-tazobactam with respect to incidence of CDAD (3.57% and 4.92%, respectively; p=0.5676), two-month in-hospital mortality (34.52% and 36.89%, respectively; p=0.7102), and composite outcome of CDAD and two-month in-hospital mortality (37.50% and 40.16%, respectively; p=0.7142). All subgroup analyses showed no difference in incidence of CDAD between the two antibiotics.

Conclusions: There was no evidence to support patients on piperacillin-tazobactam had a lower incidence of CDAD or mortality than patients on meropenem. Further research is still needed to help selecting the safest antibiotic for patients.

To read the full article Peer-reviewed Article PDF image | Peer-reviewed Full Article image

Author(s): Eugene Y H Yeung Jason G Gore Edward V Auersperg

Keywords

meropenem, piperacillin-tazobactam, Clostridium difficile, diarrhea, mortality, Saccharomyces boulardii

 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords